1. Home
  2. SHOO vs NUVB Comparison

SHOO vs NUVB Comparison

Compare SHOO & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Steven Madden Ltd.

SHOO

Steven Madden Ltd.

N/A

Current Price

$43.03

Market Cap

3.1B

ML Signal

N/A

NUVB

Nuvation Bio Inc.

N/A

Current Price

$9.07

Market Cap

2.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SHOO
NUVB
Founded
1990
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.9B
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
SHOO
NUVB
Price
$43.03
$9.07
Analyst Decision
Buy
Strong Buy
Analyst Count
8
8
Target Price
$41.00
$10.63
AVG Volume (30 Days)
960.3K
6.0M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
1.95%
N/A
EPS Growth
N/A
N/A
EPS
0.78
N/A
Revenue
$2,362,727,000.00
$26,748,000.00
Revenue This Year
$13.10
$609.55
Revenue Next Year
$11.74
$197.91
P/E Ratio
$55.13
N/A
Revenue Growth
6.41
1137.19
52 Week Low
$19.05
$1.54
52 Week High
$44.99
$9.75

Technical Indicators

Market Signals
Indicator
SHOO
NUVB
Relative Strength Index (RSI) 56.66 63.57
Support Level $42.45 $9.06
Resistance Level $43.90 $9.75
Average True Range (ATR) 1.03 0.46
MACD -0.35 -0.05
Stochastic Oscillator 22.27 65.13

Price Performance

Historical Comparison
SHOO
NUVB

About SHOO Steven Madden Ltd.

Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: